X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
index medicus (13) 13
dasatinib (10) 10
adult (9) 9
antineoplastic agents - therapeutic use (9) 9
middle aged (9) 9
aged (8) 8
chronic myelogenous leukemia (8) 8
hematology (7) 7
imatinib mesylate (7) 7
oncology (7) 7
pyrimidines - therapeutic use (7) 7
thiazoles - therapeutic use (7) 7
adolescent (6) 6
aged, 80 and over (6) 6
antineoplastic agents - adverse effects (6) 6
female (6) 6
hemic and lymphatic diseases (6) 6
male (6) 6
protein kinase inhibitors - adverse effects (6) 6
protein kinase inhibitors - therapeutic use (6) 6
pyrimidines - adverse effects (6) 6
thiazoles - adverse effects (6) 6
treatment outcome (6) 6
young adult (6) 6
abridged index medicus (5) 5
benzamides (5) 5
chronic myeloid leukemia (5) 5
follow-up studies (5) 5
fusion proteins, bcr-abl - genetics (5) 5
leukemia, myeloid, chronic-phase - drug therapy (5) 5
piperazines - therapeutic use (5) 5
therapy (5) 5
antineoplastic agents - administration & dosage (4) 4
bms-354825 (4) 4
cytogenetic responses (4) 4
imatinib (4) 4
protein kinase inhibitors - administration & dosage (4) 4
bcr-abl (3) 3
blast crisis (3) 3
cancer (3) 3
clinical trials and observations (3) 3
cml (3) 3
disease-free survival (3) 3
drug resistance, neoplasm (3) 3
failure (3) 3
follow-up (3) 3
hematology, oncology and palliative medicine (3) 3
inhibitors (3) 3
interferon-alpha (3) 3
kaplan-meier estimate (3) 3
kinase inhibitor (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (3) 3
leukemia, myeloid, chronic-phase - genetics (3) 3
piperazines - adverse effects (3) 3
piperazines - pharmacology (3) 3
pyrimidines - administration & dosage (3) 3
pyrimidines - pharmacology (3) 3
resistance (3) 3
thiazoles - administration & dosage (3) 3
accelerated phase (2) 2
asian continental ancestry group (2) 2
benzamides - therapeutic use (2) 2
child (2) 2
child development (2) 2
cytogenetic analysis (2) 2
cytogenetic response (2) 2
dasatinib - adverse effects (2) 2
dasatinib - therapeutic use (2) 2
disease progression (2) 2
dna mutational analysis (2) 2
drug administration schedule (2) 2
drug discovery - methods (2) 2
drug industry - methods (2) 2
drug resistance (2) 2
drug therapy (2) 2
drugs (2) 2
durable cytogenetic responses (2) 2
early molecular response (2) 2
european-leukemianet (2) 2
fusion proteins, bcr-abl - antagonists & inhibitors (2) 2
imatinib mesylate - adverse effects (2) 2
imatinib mesylate - therapeutic use (2) 2
kinase domain mutations (2) 2
leukemia (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - mortality (2) 2
leukemia, myeloid, chronic-phase - diagnosis (2) 2
leukemia, myeloid, chronic-phase - mortality (2) 2
medical oncology - methods (2) 2
mutation (2) 2
neoplasms (2) 2
neoplasms - drug therapy (2) 2
original reports (2) 2
paediatric oncology (2) 2
patient outcomes (2) 2
recommendations (2) 2
time factors (2) 2
tyrosine kinase inhibitors (2) 2
abl kinase domain (1) 1
achievement (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2044 - 2044
Objectives: Nivolumab, a fully human anti-programmed death-1 immunoglobulin G4 antibody, has demonstrated clinically meaningful responses and overall survival... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2016, Volume 34, Issue 23, pp. 2698 - 2704
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 583 - 583
Abstract Introduction: The programmed death-1 (PD-1) immune checkpoint pathway regulates T-cell-mediated antitumor immune responses in solid tumors and... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 24, pp. 2260 - 2270
Journal Article
Journal Article
Blood, ISSN 0006-4971, 02/2012, Volume 119, Issue 5, pp. 1123 - 1129
Journal Article
Cancer, ISSN 0008-543X, 08/2010, Volume 116, Issue 16, pp. 3852 - 3861
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 25, pp. 6322 - 6329
Dasatinib is the most potent BCR-ABL inhibitor, with 325-fold higher potency than imatinib against unmutated BCR-ABL in vitro. Studies have demonstrated the... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | TRANSFORMATION | CELLS | THERAPY | BCR-ABL | BLAST CRISIS | BMS-354825 | KINASE INHIBITOR | HEMATOLOGY | FAILURE | Follow-Up Studies | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Thiazoles - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Thiazoles - adverse effects | Young Adult | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Heart Diseases - chemically induced | Leukemia, Myeloid, Accelerated Phase - genetics | Dasatinib | Hematologic Diseases - chemically induced | Leukemia, Myeloid, Accelerated Phase - drug therapy | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - adverse effects | Piperazines - pharmacology | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Genes, abl | Pyrimidines - adverse effects | Aged | Protein Kinase Inhibitors - pharmacology | Benzamides | Mutation | Gastrointestinal Diseases - chemically induced | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 2295 - 2295
Abstract Abstract 2295 Background: During first-line BCR-ABL inhibitor therapy for CML-CP, concomitant medication use is associated with worse adherence to CML... 
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 2286 - 2286
Abstract Abstract 2286 Background: BCR-ABL kinase inhibitors dasatinib, nilotinib and imatinib have become the therapeutic mainstay for patients (pts) with... 
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 3421 - 3421
Abstract Abstract 3421 Background: BCR-ABL kinase inhibitors DAS, nilotinib and IM have become the primary treatment modality for patients (pts) with CML-CP.... 
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2016, Volume 16, Issue 6, pp. 341 - 349.e1
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 653 - 653
Abstract Background The randomized phase 3 DASISION trial in pts with newly diagnosed CML-CP has demonstrated the improved efficacy of dasatinib 100 mg once... 
Journal Article
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 2282 - 2282
Abstract Abstract 2282 Background: The Phase 3 DASISION trial comparing dasatinib 100 mg once daily with imatinib 400 mg once daily as initial treatment in... 
Journal Article
Blood, ISSN 0006-4971, 11/2010, Volume 116, Issue 21, pp. 206 - 206
Abstract Abstract 206 Background: Dasatinib is 325-fold more potent than imatinib in vitro against unmutated BCR-ABL, and is an established second-line... 
Journal Article
American Journal of Hematology, ISSN 0361-8609, 03/2010, Volume 85, Issue 3, pp. 164 - 170
Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ ALL) intolerant or resistant to imatinib. In... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | ACCELERATED PHASE | POINT MUTATIONS | RESISTANT | INTOLERANT | THERAPY | ABL KINASE DOMAIN | INHIBITORS | HEMATOLOGY | CHRONIC MYELOID-LEUKEMIA | Pleural Effusion - chemically induced | Humans | Middle Aged | Salvage Therapy | Drug Resistance, Neoplasm | Male | Neoplasm Proteins - antagonists & inhibitors | Thiazoles - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | RNA, Neoplasm - blood | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacology | Neoplasm Proteins - genetics | Dasatinib | Drug Administration Schedule | Pyrimidines - administration & dosage | src-Family Kinases - antagonists & inhibitors | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Disease Progression | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Gastrointestinal Hemorrhage - chemically induced | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | RNA, Messenger - blood | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Disease Management | Benzamides
Journal Article